Paper36073149
Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities.
Supuran CT. J Enzyme Inhib Med Chem, 2022. Cited by 60 papers, by iCite.
Cite this record
ConductScience Library. Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities. Papers, record 36073149. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36073149
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Obesity Agents | Major topic |
| Carbonic Anhydrases | Major topic |
| Carbonic Anhydrase Inhibitors | |
| Humans | |
| Obesity | |
| Sulfonamides |
Source PubMed
References78
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25590364 | Eriocitrin and Apigenin as New Carbonic Anhydrase VA Inhibitors from a Virtual Screening of Calabrian Natural Products. | Planta Med | 2015 | https://conductscience.org/library/papers/25590364 | PubMed |
| 2 | 32477270 | Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US. | Front Endocrinol (Lausanne) | 2020 | https://conductscience.org/library/papers/32477270 | PubMed |
| 3 | 30724485 | Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human Sertoli cells. | FEBS J | 2019 | https://conductscience.org/library/papers/30724485 | PubMed |
| 4 | 23607332 | Antiobesity carbonic anhydrase inhibitors: a literature and patent review. | Expert Opin Ther Pat | 2013 | https://conductscience.org/library/papers/23607332 | PubMed |
| 5 | 12617904 | Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. | Bioorg Med Chem Lett | 2003 | https://conductscience.org/library/papers/12617904 | PubMed |
| 6 | 7646445 | Role of hepatic carbonic anhydrase in de novo lipogenesis. | Biochem J | 1995 | https://conductscience.org/library/papers/7646445 | PubMed |
| 7 | 18990571 | Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes VA and VB over the cytosolic and membrane-associated carbonic anhydrases I, II and IV. | Bioorg Med Chem Lett | 2008 | https://conductscience.org/library/papers/18990571 | PubMed |
| 8 | 12684361 | Zonisamide for weight loss in obese adults: a randomized controlled trial. | JAMA | 2003 | https://conductscience.org/library/papers/12684361 | PubMed |
| 9 | 18336311 | Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? | Curr Pharm Des | 2008 | https://conductscience.org/library/papers/18336311 | PubMed |
| 10 | 18090883 | Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain? | Am J Ther | 2007 | https://conductscience.org/library/papers/18090883 | PubMed |
| 11 | 11225714 | Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. | Obes Res | 2000 | https://conductscience.org/library/papers/11225714 | PubMed |
| 12 | 21300547 | (R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases. | Bioorg Med Chem Lett | 2011 | https://conductscience.org/library/papers/21300547 | PubMed |
| 13 | 33066524 | Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment. | Metabolites | 2020 | https://conductscience.org/library/papers/33066524 | PubMed |
| 14 | 27268752 | Active Components of Essential Oils as Anti-Obesity Potential Drugs Investigated by in Silico Techniques. | J Agric Food Chem | 2016 | https://conductscience.org/library/papers/27268752 | PubMed |
| 15 | 21481449 | Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. | Lancet | 2011 | https://conductscience.org/library/papers/21481449 | PubMed |
| 16 | 31387062 | A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors. | Eur J Med Chem | 2019 | https://conductscience.org/library/papers/31387062 | PubMed |
| 17 | 22607219 | Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? | Chem Rev | 2012 | https://conductscience.org/library/papers/22607219 | PubMed |
| 18 | 18618322 | Carbonic anhydrase inhibitors. Cloning, characterization and inhibition studies of the cytosolic isozyme III with anions. | J Enzyme Inhib Med Chem | 2009 | https://conductscience.org/library/papers/18618322 | PubMed |
| 19 | 9246356 | Short-term regulation of acetyl CoA carboxylase in tissues of higher animals. | Prog Lipid Res | 1996 | https://conductscience.org/library/papers/9246356 | PubMed |
| 20 | 33647280 | Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target. | Gastroenterology | 2021 | https://conductscience.org/library/papers/33647280 | PubMed |
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 60 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42873864 | Mitochondrial carbonic anhydrase-VB inhibition rescues brain endothelial stress and memory in Alzheimer's disease models. | Sci Adv | 2026 | https://conductscience.org/library/papers/42873864 | PubMed |
| 42511717 | Carbonic Anhydrase I and II as Biomarkers and Therapeutic Targets in Human Disease: From Physiology to Clinical Translation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511717 | PubMed |
| 42062767 | Future Directions in Biotechnological and Pharmacological Applications of CAIs. | Subcell Biochem | 2026 | https://conductscience.org/library/papers/42062767 | PubMed |
| 42062761 | Computational Approaches and Structure-Based Drug Design of CAIs. | Subcell Biochem | 2026 | https://conductscience.org/library/papers/42062761 | PubMed |
| 42004439 | Exposure to topiramate may not increase the risk of urolithiasis: A nationwide cohort study. | Epilepsy Behav Rep | 2026 | https://conductscience.org/library/papers/42004439 | PubMed |
| 41827842 | Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy. | Cells | 2026 | https://conductscience.org/library/papers/41827842 | PubMed |
| 41333660 | Establishment, validation and application of a spectrophotometric method for the accurate determination of carbonic anhydrase activity. | RSC Adv | 2025 | https://conductscience.org/library/papers/41333660 | PubMed |
| 41089480 | Human Carbonic Anhydrase Inhibitors. | ACS Med Chem Lett | 2025 | https://conductscience.org/library/papers/41089480 | PubMed |
| 41078454 | Synergistic Effects of Dietary Protein and Vitamin E Intake on Reducing Metabolic-Associated Fatty Liver Disease Risk: Insights From NHANES [2017-2023] and Mendelian Randomization Study. | Food Sci Nutr | 2025 | https://conductscience.org/library/papers/41078454 | PubMed |
| 40955181 | Pyrrolidine-based hybrid compounds: design, synthesis, in vitro and in vivo pharmacological properties and molecular docking studies. | Future Med Chem | 2025 | https://conductscience.org/library/papers/40955181 | PubMed |
| 40559425 | Bile Acids and Type 2 Diabetes: Roles in Glucose Homeostasis and Therapeutic Opportunities. | Metabolites | 2025 | https://conductscience.org/library/papers/40559425 | PubMed |
| 40553229 | Phenolic Extracts with Antioxidant and Anticancer Potential from Araticum Fruits (Annona crassiflora Mart.), a Native Brazilian Plant. | Plant Foods Hum Nutr | 2025 | https://conductscience.org/library/papers/40553229 | PubMed |
| 40534661 | Multi-Target Glitazones for Modulating Peroxisome Proliferator-Activated Receptor-γ, Cyclooxygenase-2, and Carbonic Anhydrases for the Management of Metabolic Dysfunction. | ACS Pharmacol Transl Sci | 2025 | https://conductscience.org/library/papers/40534661 | PubMed |
| 40257393 | Discover the Power of Lithospermic Acid as Human Carbonic Anhydrase VA and Pancreatic Lipase Inhibitor Through In Silico and In Vitro Studies. | Arch Pharm (Weinheim) | 2025 | https://conductscience.org/library/papers/40257393 | PubMed |
| 40123420 | Dual inhibition of carbonic anhydrases VA and VII by silychristin and isosilybin A from Silybum marianum: A potential antiobesity strategy. | Arch Pharm (Weinheim) | 2025 | https://conductscience.org/library/papers/40123420 | PubMed |
| 39968288 | Synthesis, characterization, antimicrobial, cytotoxic and carbonic anhydrase inhibition activities of multifunctional pyrazolo-1,2-benzothiazine acetamides. | Beilstein J Org Chem | 2025 | https://conductscience.org/library/papers/39968288 | PubMed |
| 39821584 | Effects of defined voluntary running distances coupled with high-fat diet consumption on the skeletal muscle transcriptome of male mice. | Physiol Rep | 2025 | https://conductscience.org/library/papers/39821584 | PubMed |
| 39534850 | Exploring heterocyclic scaffolds in carbonic anhydrase inhibition: a decade of structural and therapeutic insights. | RSC Adv | 2024 | https://conductscience.org/library/papers/39534850 | PubMed |
| 39062004 | Phytochemical Characterization and Antioxidant Activity Evaluation for Some Plant Extracts in Conjunction with Pharmacological Mechanism Prediction: Insights into Potential Therapeutic Applications in Dyslipidemia and Obesity. | Biomedicines | 2024 | https://conductscience.org/library/papers/39062004 | PubMed |
| 38998967 | Synthesis and Enzymatic Evaluation of a Small Library of Substituted Phenylsulfonamido-Alkyl Sulfamates towards Carbonic Anhydrase II. | Molecules | 2024 | https://conductscience.org/library/papers/38998967 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACACA | 31 | PubTator's text mining | https://conductscience.org/library/genes/31 | NCBI Gene |
| CA1 | 759 | PubTator's text mining | https://conductscience.org/library/genes/759 | NCBI Gene |
| CA2 | 760 | PubTator's text mining | https://conductscience.org/library/genes/760 | NCBI Gene |
| CA3 | 761 | PubTator's text mining | https://conductscience.org/library/genes/761 | NCBI Gene |
| CYP24A1 | 1591 | PubTator's text mining | https://conductscience.org/library/genes/1591 | NCBI Gene |
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GIP | 2695 | PubTator's text mining | https://conductscience.org/library/genes/2695 | NCBI Gene |
| HCA1 | 266790 | PubTator's text mining | https://conductscience.org/library/genes/266790 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| PC | 5091 | PubTator's text mining | https://conductscience.org/library/genes/5091 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36073149
GET https://conductscience.org/api/papers/v1/36073149/references?page=2